Introduction

Depression is a pervasive mental health condition affecting millions globally. It is characterized by persistent sadness, lack of interest in daily activities, and cognitive impairments, significantly reducing quality of life.¹ While traditional treatments, including selective serotonin reuptake inhibitors (SSRIs) and psychotherapy, are effective for some, many patients experience suboptimal outcomes or adverse side effects.²

Recently, medical cannabis has emerged as a potential therapeutic option for depression. Its active compounds, tetrahydrocannabinol (THC) and cannabidiol (CBD), interact with the endocannabinoid system (ECS), which plays a vital role in mood regulation. However, the effects of cannabis vary significantly between individuals due to differences in biology, genetics, and environmental factors. This highlights the necessity of a personalised approach to maximise therapeutic benefits while minimising risks.³

Understanding cannabis as a therapeutic option

Cannabis compounds and their effects

Cannabis contains over 100 phytocannabinoids, with THC and CBD being the most studied. THC is psychoactive and can elevate mood but may induce anxiety or psychosis in sensitive individuals. In contrast, CBD is non-psychoactive and has anxiolytic and anti-inflammatory properties, potentially counteracting some adverse effects of THC.⁴

Mechanism of action

The ECS comprises endocannabinoids, receptors (CB1 and CB2), and enzymes that regulate physiological processes, including mood, appetite, and stress response. THC primarily activates CB1 receptors in the brain, influencing neurotransmitter release and mood regulation. CBD, on the other hand, modulates receptor activity indirectly and interacts with serotonin receptors, enhancing its antidepressant potential.⁵

Challenges in cannabis use for depression

Despite its promise, cannabis use poses risks. THC can impair cognition, induce dependence, and worsen symptoms in vulnerable populations. Furthermore, the lack of standardised cannabis products complicates dose optimisation, underscoring the need for individualised approaches.⁶

The role of personalisation in cannabis treatment

Biological differences among individuals

Genetic variations influence how individuals metabolise cannabis. Polymorphisms in the cytochrome P450 enzymes (e.g., CYP2C9, CYP3A4) affect THC and CBD metabolism, altering their therapeutic and side effects. Additionally, genetic differences in ECS components, such as the CNR1 gene encoding CB1 receptors, contribute to variability in responses.⁷

Psychological and behavioral considerations

A patient’s mental health history significantly impacts cannabis treatment outcomes. For instance, individuals with a history of anxiety may benefit more from CBD-dominant products, while those with melancholic depression might respond better to balanced THC: CBD formulations. Behavioural factors, such as tolerance and previous cannabis use, also influence efficacy.⁷

Lifestyle and environmental factors

Diet, physical activity, and concurrent medications can modify cannabis’s effects. For instance, high-fat meals enhance THC absorption, potentially intensifying psychoactive effects. Environmental stressors, such as social isolation, may also modulate the therapeutic response to cannabis.⁸

Benefits of a personalised approach

Improved efficacy

Personalised treatment allows clinicians to tailor cannabis strains, THC: CBD ratios, and delivery methods (e.g., vaporisation, tinctures) to individual needs, optimising symptom relief. For example, high-CBD strains may alleviate anxiety in depression, while low-dose THC may improve mood and sleep.[9]

Enhanced safety

Customising treatment minimises risks of adverse effects such as dependence or THC-induced anxiety. By monitoring and adjusting doses based on individual tolerance, clinicians can achieve therapeutic goals with minimal harm.¹⁰

Holistic patient care

A personalised approach integrates cannabis treatment with conventional therapies, such as cognitive-behavioural therapy (CBT) and lifestyle modifications. This synergy enhances overall mental health outcomes, addressing the multifaceted nature of depression.[11]

Implementation of personalisation in practice

Assessment and diagnosis

A thorough patient evaluation is the cornerstone of personalised cannabis treatment. This includes medical history, mental health assessments, and genetic testing to predict cannabis metabolism and ECS function.¹²

Developing a treatment plan

Based on assessment results, clinicians can recommend specific cannabis products. For example, a patient with high anxiety sensitivity may start with a CBD-rich strain at a low dose and gradually titrate to achieve the desired effects. Delivery methods, such as sublingual oils for steady absorption, can also be customised.¹³

Monitoring and adjustments

Regular follow-ups are critical to assess efficacy, side effects, and patient satisfaction. Clinicians can adjust doses, switch strains, or explore alternative therapies based on real-time feedback. Advanced tools, such as digital health apps, can facilitate tracking and enhance patient engagement.¹⁴

Challenges in personalising cannabis treatment

Regulatory and legal barriers

Inconsistent regulations across regions hinder access to standardised cannabis products, complicating personalisation. For instance, THC content limits vary widely, affecting product availability and treatment consistency.¹⁵

Knowledge gaps in clinical research

Despite promising preclinical evidence, robust clinical trials on cannabis for depression remain limited. This restricts evidence-based guidelines for personalisation, necessitating more targeted research.

Economic and accessibility issues

Personalised treatment often involves costly genetic testing and specialised products, posing affordability challenges. Ensuring equitable access requires policy support and insurance coverage for medical cannabis.¹⁶

Future directions

Advancing research on personalised cannabis medicine

Large-scale clinical trials focusing on genetic, biological, and psychological predictors of cannabis response are essential. Biomarkers, such as endocannabinoid levels, could guide precision treatment.

Education and training for healthcare providers

Healthcare professionals need comprehensive training on cannabis pharmacology, therapeutic applications, and personalisation strategies to provide safe and effective care.¹⁷

Integration into mainstream healthcare

Collaboration between traditional healthcare systems and cannabis-focused practitioners can facilitate holistic, patient-centred care. Policy reforms promoting research, standardisation, and accessibility will further integration efforts.¹⁸

Summary

In conclusion, a personalised approach to cannabis treatment for depression offers significant potential to enhance therapeutic outcomes by addressing individual differences in biology, psychology, and lifestyle. Tailoring cannabis strains, THC: CBD ratios, and delivery methods ensures optimal efficacy while minimising adverse effects.

Despite challenges such as limited research, regulatory hurdles, and accessibility issues, advancing scientific understanding and fostering supportive healthcare policies can help integrate personalised cannabis therapies into mainstream mental healthcare. This approach holds promise for improving the quality of life for individuals with depression by providing safer, more effective, and patient-centred treatment options